Harini Sarathy

Harini Sarathy

Auto-generated profile, based on publicly available information

Harini Sarathy

Division of Nephrology, University of California San Francisco, San Francisco, California

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Hypertension
Verified
Journal Article
Open access
JCJennifer L. Cluett
Jennifer L. Cluett
OBOlivia Blazek
Olivia Blazek
ABAngela L. Brown
Angela L. Brown
CECara East
Cara East
KFKeith C. Ferdinand
Keith C. Ferdinand
ODon behalf of the American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on the Kidney in Cardiovascular Disease; and Council on Peripheral Vascular Disease
on behalf of the American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on the Kidney in Cardiovascular Disease; and Council on Peripheral Vascular Disease
Hypertension is a leading risk factor for cardiovascular morbidity and mortality. Despite the widespread availability of both pharmacological and lifestyle therapeutic options, blood pressure control rates across the globe are worsening. In fact, only 23% of individuals with high blood pressure in the United States achieve treatment goals. In 2023, the US Food and Drug Administration approved renal denervation, a catheter-based procedure that ablates the renal sympathetic nerves, as an adjunctive treatment for patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. This approval followed the publication of multiple randomized clinical studies using rigorous trial designs, all incorporating renal angiogram as the sham control. Most but not all of the new generation of trials reached their primary end point, demonstrating modest efficacy of renal denervation in lowering blood pressure across a spectrum of hypertension, from mild to truly resistant. Individual patient responses vary, and further research is needed to identify those who may benefit most. The initial safety profile appears favorable, and multiple ongoing studies are assessing longer-term efficacy and safety. Multidisciplinary teams that include hypertension specialists and adequately trained proceduralists are crucial to ensure that referrals are made appropriately with full consideration of the potential risks and benefits. Incorporating patient preferences and engaging in shared decision-making conversations will help patients make the best decisions given their individual circumstances. Although further research is clearly needed, renal denervation presents a novel treatment strategy for patients with uncontrolled blood pressure.

10 December 2020 in Journal of the American Geriatrics Society
Verified
Journal Article
Open access
PDF file
JAJonathan G. Amatruda
Jonathan G. Amatruda
RKRonit Katz
Ronit Katz
CPCarmen A. Peralta
Carmen A. Peralta
MEMichelle M. Estrella
Michelle M. Estrella
HSHarini Sarathy
Harini Sarathy
FSfor the Health ABC Study
for the Health ABC Study
Background/Objectives: Non‐steroidal anti‐inflammatory drugs (NSAIDs) can cause kidney injury, especially in older adults. However, previously reported associations between NSAID use and kidney health outcomes are inconsistent and limited by reliance on serum creatinine‐based GFR estimates. This analysis investigated the association of NSAID use with kidney damage in older adults using multiple kidney health measures. Design: Cross‐sectional and longitudinal analyses. Setting: Multicenter, community‐based cohort. Participants: Two thousand nine hundred and ninty nine older adults in the Health ABC Study. A subcohort (n = 500) was randomly selected for additional biomarker measurements. Exposure: Prescription and over‐the‐counter NSAID use ascertained by self‐report. Measurements: Baseline estimated glomerular filtration rate (eGFR) by cystatin C (cysC), urine albumin‐to‐creatinine ratio (ACR), kidney injury molecule‐1 (KIM‐1), and interleukin‐18 (IL‐18) were measured in 2,999 participants; alpha‐1 microglobulin (α1m), neutrophil gelatinase‐associated lipocalin (NGAL), propeptide type III procollagen (PIIINP), and uromodulin (UMOD) were measured in 500 participants. GFR was estimated three times over 10 years and expressed as percent change per year. Results: Participants had a mean age of 74 years, 51% were female, and 41% African‐American. No eGFR differences were detected between NSAID users (n = 655) and non‐users (n = 2,344) at baseline (72 ml/min/1.73 m 2 in both groups). Compared to non‐users, NSAID users had lower adjusted odds of having ACR greater than 30 mg/g (0.67; 95% confidence interval (CI) = 0.51–0.89) and lower mean urine IL‐18 concentration at baseline (−11%; 95% CI = −4% to −18%), but similar mean KIM‐1 (5%; 95% CI = −5% to 14%). No significant differences in baseline concentrations of the remaining urine biomarkers were detected. NSAID users and non‐users did not differ significantly in the rate of eGFR decline (−2.2% vs ‐2.3% per year). Conclusion: Self‐reported NSAID use was not associated with kidney dysfunction or injury based on multiple measures, raising the possibility of NSAID use without kidney harm in ambulatory older adults. More research is needed to define safe patterns of NSAID consumption.

6 October 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
LWLeslie Wilson
Leslie Wilson
AGAnne F. Gress
Anne F. Gress
LFLynda Frassetto
Lynda Frassetto
HSHarini Sarathy
Harini Sarathy
EGElizabeth A. Gress
Elizabeth A. Gress
Shuvo RoyShuvo Roy
Shuvo Roy
Background: Next-generation implantable and wearable KRTs may revolutionize the lives of patients undergoing dialysis by providing more frequent and/or prolonged therapy along with greater mobility compared with in-center hemodialysis. Medical device innovators would benefit from patient input to inform product design and development. Our objective was to determine key risk/benefit considerations for patients with kidney failure and test how these trade-offs could drive patient treatment choices. Methods: We developed a choice-based conjoint discrete choice instrument and surveyed 498 patients with kidney failure. The choice-based conjoint instrument consisted of nine attributes of risk and benefit pertinent across KRT modalities. Attributes were derived from literature reviews, patient/clinician interviews, and pilot testing. The risk attributes were serious infection, death within 5 years, permanent device failure, surgical requirements, and follow-up requirements. The benefit attributes were fewer diet restrictions, improved mobility, pill burden, and fatigue. We created a random, full-profile, balanced overlap design with 14 choice pairs plus five fixed tasks to test validity. We used a mixed-effects regression model with attribute levels as independent predictor variables and choice decisions as dependent variables. Results: All variables were significantly important to patient choice preferences, except follow-up requirements. For each 1% higher risk of death within 5 years, preference utility was lower by 2.22 (β=−2.22; 95% confidence interval [CI], −2.52 to −1.91), while for each 1% higher risk of serious infection, utility was lower by 1.38 (β=−1.46; 95% CI, −1.77 to −1.00) according to comparisons of the β coefficients. Patients were willing to trade a 1% infection risk and 0.5% risk of death to gain complete mobility and freedom from in-center hemodialysis (β=1.46; 95% CI, 1.27 to 1.64). Conclusions: Despite an aversion to even a 1% higher risk of death within 5 years, serious infection, and permanent device rejection, patients with kidney failure suggested that they would trade these risks for the benefit of complete mobility.

1 September 2021 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
HSHarini Sarathy
Harini Sarathy
JCJordana B. Cohen
Jordana B. Cohen

4 April 2022 in The Lancet
Verified
Journal Article
Closed access
HSHarini Sarathy
Harini Sarathy
LSLiann Abu Salman
Liann Abu Salman

27 October 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
NBNisha Bansal
Nisha Bansal
MRMatthew Rivara
Matthew Rivara
HSHarini Sarathy
Harini Sarathy
CCCarlyn Clark
Carlyn Clark
JPJulie Porter
Julie Porter
BWBryan J. Weiner
Bryan J. Weiner